Guardant Health Inc. Stock News

The bottom line about the stock market is that it is a popularity contest. That's because there is no one true way to determine the exact value of a stock.

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term b

After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simp

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list,

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studi

From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Admini

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Mol

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Willia

DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal am

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Unio

Amalgamated Bank cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securi